BiotechTube

Simvastatin + acetylsalicylic acid (ASA) + omefas

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia

Trial Timeline

Nov 1, 2011 → Mar 1, 2012

NCT ID
NCT01486433

About Simvastatin + acetylsalicylic acid (ASA) + omefas

Simvastatin + acetylsalicylic acid (ASA) + omefas is a phase 1 stage product being developed by AstraZeneca for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01486433. Target conditions include Hypertriglyceridemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01486433Phase 1Completed

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors
ProductCompanyStageHype Score
LY3875383 + PlaceboEli LillyPhase 1
33
ZYH7 + ZYH7 + ZYH7 + FenofibrateZydus LifesciencesPhase 2
52
Solbinsiran + PlaceboEli LillyPhase 2
52
Placebo + Ethyl IcosapentateSumitomo PharmaPhase 3
77
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn OilJiangsu Hengrui MedicinePhase 3
77
warfarin + omefas + omega-3-acid ethyl estersAstraZenecaPhase 1
33
rosuvastatinAstraZenecaApproved
85
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4gAstraZenecaPhase 3
77
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)AstraZenecaPhase 2
52
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hoursAstraZenecaPhase 1
33
placebo + omefas + omefas + omefasAstraZenecaPhase 2/3
65
Epanova + LovazaAstraZenecaPhase 1
33
Epanova + Olive OilAstraZenecaPhase 3
77
AZD0585 + AZD0585 placeboAstraZenecaPhase 3
77
ABT-143 + simvastatinAstraZenecaPhase 3
77
MaravirocPfizerPhase 1
32
torcetrapib/atorvastatin + atorvastatinPfizerPhase 3
76
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)Mochida PharmaceuticalPhase 3
76
IcosapentMochida PharmaceuticalPhase 3
76
REGN1500 + placeboRegeneron PharmaceuticalsPhase 1
32

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85